Literature DB >> 4043665

Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy.

A J Stellon, A Davies, J Compston, R Williams.   

Abstract

To determine the frequency of osteoporosis in patients with autoimmune chronic active hepatitis who are maintained on corticosteroids, both cortical and trabecular bone loss were studied in a group of 36 patients. A significant decrease in both the total trabecular bone volume (p = 0.005) and cortical plate thickness (p = 0.01) of iliac crest biopsy specimens was found in the patients with chronic active hepatitis. Bone mineral content of the radial metaphysis, a site composed of both cortical and trabecular bone, was found to be significantly decreased (p = 0.05). However, no statistical reduction in cortical bone mass of the radial diaphysis and second metacarpal was detected. Altogether, 47% of patients had evidence of either excessive trabecular or cortical bone loss, or both, as judged by histologic and radiologic criteria. The presence of cirrhosis at the time of diagnosis or subsequently did not appear to lead to greater loss of bone mass. However, a weak inverse correlation was found between the product of mean dose and duration of corticosteroid therapy and both the trabecular bone volume and the cortical plate thickness of the iliac crest biopsy specimens. Based on these results, patients with autoimmune chronic active hepatitis on low doses of prednisolone therapy may need to be treated with calcium and vitamin D at an early stage of their disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4043665     DOI: 10.1016/0016-5085(85)90212-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  15 in total

1.  Bone histomorphometry in Cushing's syndrome.

Authors:  A Borelli; M O Leite; P H Correa; V Jorgetti; J A Marcondes; J R Batalha; A B Cintra; B L Wajchenberg
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

2.  Bone mineral densities in individuals with Gilbert's syndrome: a cross-sectional, case-control pilot study.

Authors:  G Y Minuk; R Greenberg; J Uhanova; K Hawkins; W D Leslie
Journal:  Can J Gastroenterol       Date:  2009-06       Impact factor: 3.522

Review 3.  Bone disease after liver transplantation.

Authors:  M S Losowsky; S H Hussaini
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

Review 4.  Autoimmune Hepatitis Beyond Steroids: Effective Trial Design and Attention to Quality of Life.

Authors:  Christoph Schramm
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-08-02

5.  Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis.

Authors:  A J Stellon; A Webb; J E Compston
Journal:  Gut       Date:  1988-03       Impact factor: 23.059

6.  Osteoporosis and skeletal fractures in chronic liver disease.

Authors:  T Diamond; D Stiel; M Lunzer; M Wilkinson; J Roche; S Posen
Journal:  Gut       Date:  1990-01       Impact factor: 23.059

Review 7.  Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease.

Authors:  J E Compston
Journal:  Gut       Date:  1986-09       Impact factor: 23.059

8.  Amount and composition of bone minerals in chronic liver disease.

Authors:  J A Kalef-Ezra; M H Merkouropoulos; A Challa; J Hatzikonstantinou; A H Karantanas; E V Tsianos
Journal:  Dig Dis Sci       Date:  1996-05       Impact factor: 3.199

Review 9.  Drug therapy in the management of type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

10.  Bone disease in vitamin D-deficient patients with Crohn's disease.

Authors:  H Vogelsang; P Ferenci; W Woloszczuk; H Resch; C Herold; S Frotz; A Gangl
Journal:  Dig Dis Sci       Date:  1989-07       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.